PharmAthene, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2001-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.pharmathene.com
Dose Escalation Study of Valortim® (MDX-1303) Administered Intravenously (IV) in Healthy, Normal Subjects
Phase 1
Completed
- Conditions
- Anthrax
- Interventions
- Biological: MDX1303Drug: Normal Saline for Injection
- First Posted Date
- 2010-12-23
- Last Posted Date
- 2013-12-09
- Lead Sponsor
- PharmAthene, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT01265745
- Locations
- 🇺🇸
Quintiles Phase I Unit, Overland Park, Kansas, United States
Study of Valortim® (MDX-1303) and Its Selected Formulation Components Percutaneous Use
Phase 1
Completed
- Conditions
- Allergic Reactions
- Interventions
- Drug: Valortim and Selected Components
- First Posted Date
- 2010-09-17
- Last Posted Date
- 2010-09-24
- Lead Sponsor
- PharmAthene, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT01204866
- Locations
- 🇺🇸
Kansas City Allergy and Asthma, Overland Park, Kansas, United States
Ph1 Study of Valortim and Doxycycline in Humans
Phase 1
Terminated
- Conditions
- Anthrax
- Interventions
- Drug: Placebo Antibiotic and ValortimDrug: Placebo Antibiotic and Placebo Valortim
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2010-08-10
- Lead Sponsor
- PharmAthene, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00964834
- Locations
- 🇺🇸
Quintiles Phase I Services, Overland Park, Kansas, United States
Ph1 Study of Valortim and Ciprofloxacin in Humans
Phase 1
Suspended
- Conditions
- Anthrax
- Interventions
- Other: Placebo Antibiotic and Placebo ValortimDrug: Placebo Antibiotic and Valortim
- First Posted Date
- 2009-08-25
- Last Posted Date
- 2010-08-10
- Lead Sponsor
- PharmAthene, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT00964561
- Locations
- 🇺🇸
Quintiles Phase I Services, Overland Park, Kansas, United States
First Time in Human Study of Protexia
Phase 1
Completed
- Conditions
- Intervention for Nerve Agent Exposure
- Interventions
- Biological: Protexia
- First Posted Date
- 2008-08-29
- Last Posted Date
- 2010-09-17
- Lead Sponsor
- PharmAthene, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT00744146
- Locations
- 🇺🇸
Quinitles Phase I Services, Overland Park, Kansas, United States
© Copyright 2025. All Rights Reserved by MedPath